Herantis Pharma Plc

Biotechnology ResearchFinland11-50 Employees

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’s lead product, HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration. Primary objective of the ongoing Phase 1b clinical trial is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers and monitor symptoms associated with Parkinson’s disease. Topline data from Phase 1b trial is expected in September 2025. The Phase 1b trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Parkinson’s Virtual Biotech. Herantis is listed on the Nasdaq First North Growth Market Finland.

Sign up for free to view info

Email Format Employee directory